- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanostart subsidiary MagForce Nanotechnologies AG, a medical technology company listed in the Entry Standard segment of the Frankfurt Stock Exchange, today announced its intention to increase its share capital under the procedure to exclude subscription rights for existing investors.
The company's nominal capital is EUR 3,773,198.00, divided into 3,773,198 common shares in bearer form with an imputed nominal value of EUR 1.00. In its resolution of the June 16, 2010, approved by the supervisory board on June 16, 2010, the executive board of MagForce Nanotechnologies has decided to increase its share capital by up to EUR 80,190 against cash contributions, bringing its approved capital limit up to EUR 3,853,388.
Up to 80,190 new common shares will be issued, with profit participation rights dating from January 1, 2009. The company has excluded subscription rights to existing shareholders by its authority under sec. 6 para. 3 of its articles of incorporation (Satzung). The new shares will be privately placed with German and international institutional investors at an offering price of EUR 42.00 per share.
The proceeds of the capital increase are to be used to finance the company's further growth.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
About MagForce Nanotechnologies
MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. Its patented Nano-Cancer® therapy enables the targeted destruction of tumors using superparamagnetic nanoparticles to generate heat. The nanotechnology from MagForce represents a revolutionary approach to the future successful treatment of solid tumors.
For more information, please click here
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © NanostartIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Graphenea embarks on a new era April 16th, 2015
Arrowhead to Report Fiscal 2015 First Quarter Financial Results February 2nd, 2015
Graphenea sales more than double in 2014 January 29th, 2015